RAB5A and chronic myelogenous leukemia, BCR-ABL1 positive: The results were presented in Figure 3B. Interestingly, the qRT-PCR analysis revealed a significant downregulation of RAB5A in CML patients at diagnosis (Diagnosis, mean −0.98; CI 1.34–2.69; t-test p << 0.01), during secondary resistance (Relapse, mean −0.97; CI 1.25–2.77; t-test p << 0.01), and in primary resistant subjects (Resistant, mean −2.46; CI 0.53–6.46; t-test p = 0.02) compared to healthy controls (mean +1.04) (Figure 3B, upper panel).